Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 295

1.

Effect on Cognition of Estroprogestins Combined with Interferon Beta in Multiple Sclerosis: Analysis of Secondary Outcomes from a Randomised Controlled Trial.

De Giglio L, Marinelli F, Barletta VT, Pagano VA, De Angelis F, Fanelli F, Petsas N, Pantano P, Tomassini V, Pozzilli C.

CNS Drugs. 2016 Dec 19. [Epub ahead of print]

PMID:
27995531
2.

Extratemporal herpes encephalitis during natalizumab treatment: A case report.

Haggiag S, Prosperini L, Galgani S, Pozzilli C, Pinnetti C.

Mult Scler Relat Disord. 2016 Nov;10:134-136. doi: 10.1016/j.msard.2016.10.002.

PMID:
27919480
3.

Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis.

Prosperini L, Saccà F, Cordioli C, Cortese A, Buttari F, Pontecorvo S, Bianco A, Ruggieri S, Haggiag S, Brescia Morra V, Capra R, Centonze D, Di Battista G, Ferraro E, Francia A, Galgani S, Gasperini C, Millefiorini E, Mirabella M, Pozzilli C.

J Neurol. 2016 Nov 22. [Epub ahead of print]

PMID:
27878443
4.

Corpus callosum microstructural changes associated with Kawashima Nintendo Brain Training in patients with multiple sclerosis.

De Giglio L, Upadhyay N, De Luca F, Prosperini L, Tona F, Petsas N, Pozzilli C, Pantano P.

J Neurol Sci. 2016 Nov 15;370:211-213. doi: 10.1016/j.jns.2016.09.041. No abstract available.

PMID:
27772761
5.

Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy.

Laroni A, Brogi D, Brescia Morra V, Guidi L, Pozzilli C, Comi G, Lugaresi A, Turrini R, Raimondi D, Uccelli A, Mancardi GL.

Neurol Sci. 2016 Oct 18. [Epub ahead of print]

PMID:
27757552
6.

A lesion topography-based approach to predict the outcomes of patients with multiple sclerosis treated with Interferon Beta.

Galassi S, Prosperini L, Logoteta A, Hirsch MN, Fanelli F, De Giglio L, Pozzilli C.

Mult Scler Relat Disord. 2016 Jul;8:99-106. doi: 10.1016/j.msard.2016.05.012.

PMID:
27456883
7.

Tp-Te interval predicts heart rate reduction after fingolimod administration in patients with multiple sclerosis.

Tocci G, Giuliani M, Canichella F, Timpano J, Presta V, Francia P, Musumeci MB, Fubelli F, Pozzilli C, Volpe M, Ferrucci A.

Int J Cardiol. 2016 Oct 15;221:881-5. doi: 10.1016/j.ijcard.2016.07.134.

PMID:
27434365
8.

Dentate nucleus connectivity in adult patients with multiple sclerosis: functional changes at rest and correlation with clinical features.

Sbardella E, Upadhyay N, Tona F, Prosperini L, De Giglio L, Petsas N, Pozzilli C, Pantano P.

Mult Scler. 2016 Jul 13. pii: 1352458516657438. [Epub ahead of print]

PMID:
27411700
9.

The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study.

D'Amico E, Leone C, Graziano G, Amato MP, Bergamaschi R, Cavalla P, Coniglio G, Di Battista G, Ferrò MT, Granella F, Granieri E, Lugaresi A, Lus G, Millefiorini E, Pozzilli C, Tedeschi G, Zappia M, Comi G, Trojano M, Lepore V, Patti F.

PLoS One. 2016 Jun 27;11(6):e0157721. doi: 10.1371/journal.pone.0157721.

10.

Assessing response to interferon-β in a multicenter dataset of patients with MS.

Sormani MP, Gasperini C, Romeo M, Rio J, Calabrese M, Cocco E, Enzingher C, Fazekas F, Filippi M, Gallo A, Kappos L, Marrosu MG, Martinelli V, Prosperini L, Rocca MA, Rovira A, Sprenger T, Stromillo ML, Tedeschi G, Tintorè M, Tortorella C, Trojano M, Montalban X, Pozzilli C, Comi G, De Stefano N; MAGNIMS study group..

Neurology. 2016 Jul 12;87(2):134-40. doi: 10.1212/WNL.0000000000002830.

PMID:
27306626
11.

Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study.

Gold R, Arnold DL, Bar-Or A, Hutchinson M, Kappos L, Havrdova E, MacManus DG, Yousry TA, Pozzilli C, Selmaj K, Sweetser MT, Zhang R, Yang M, Potts J, Novas M, Miller DH, Kurukulasuriya NC, Fox RJ, Phillips TJ.

Mult Scler. 2016 May 19. pii: 1352458516649037. [Epub ahead of print]

PMID:
27207449
12.

A dual concurrent mechanism explains trigeminal neuralgia in patients with multiple sclerosis.

Truini A, Prosperini L, Calistri V, Fiorelli M, Pozzilli C, Millefiorini E, Frontoni M, Cortese A, Caramia F, Cruccu G.

Neurology. 2016 May 31;86(22):2094-9. doi: 10.1212/WNL.0000000000002720.

PMID:
27164695
13.

Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity.

Patti F, Messina S, Solaro C, Amato MP, Bergamaschi R, Bonavita S, Bruno Bossio R, Brescia Morra V, Costantino GF, Cavalla P, Centonze D, Comi G, Cottone S, Danni M, Francia A, Gajofatto A, Gasperini C, Ghezzi A, Iudice A, Lus G, Maniscalco GT, Marrosu MG, Matta M, Mirabella M, Montanari E, Pozzilli C, Rovaris M, Sessa E, Spitaleri D, Trojano M, Valentino P, Zappia M; SA.FE. study group..

J Neurol Neurosurg Psychiatry. 2016 Sep;87(9):944-51. doi: 10.1136/jnnp-2015-312591.

14.

Long-term assessment of No Evidence of Disease Activity with natalizumab in relapsing multiple sclerosis.

Prosperini L, Fanelli F, Pozzilli C.

J Neurol Sci. 2016 May 15;364:145-7. doi: 10.1016/j.jns.2016.03.025.

PMID:
27084235
15.

The effect of inflammation and its reduction on brain plasticity in multiple sclerosis: MRI evidence.

Tomassini V, d'Ambrosio A, Petsas N, Wise RG, Sbardella E, Allen M, Tona F, Fanelli F, Foster C, Carnì M, Gallo A, Pantano P, Pozzilli C.

Hum Brain Mapp. 2016 Jul;37(7):2431-45. doi: 10.1002/hbm.23184.

16.

Multiple Sclerosis: Changes in Thalamic Resting-State Functional Connectivity Induced by a Home-based Cognitive Rehabilitation Program.

De Giglio L, Tona F, De Luca F, Petsas N, Prosperini L, Bianchi V, Pozzilli C, Pantano P.

Radiology. 2016 Jul;280(1):202-11. doi: 10.1148/radiol.2016150710.

PMID:
26953867
17.

Prevalence of multiple sclerosis in the Lazio region, Italy: use of an algorithm based on health information systems.

Bargagli AM, Colais P, Agabiti N, Mayer F, Buttari F, Centonze D, Di Folco M, Filippini G, Francia A, Galgani S, Gasperini C, Giuliani M, Mirabella M, Nociti V, Pozzilli C, Davoli M.

J Neurol. 2016 Apr;263(4):751-9. doi: 10.1007/s00415-016-8049-8.

18.

The cognitive reserve theory in the setting of pediatric-onset multiple sclerosis.

Pastò L, Portaccio E, Goretti B, Ghezzi A, Lori S, Hakiki B, Giannini M, Righini I, Razzolini L, Niccolai C, Moiola L, Falautano M, Simone M, Viterbo RG, Patti F, Cilia S, Pozzilli C, Bianchi V, Roscio M, Martinelli V, Comi G, Trojano M, Amato MP; MS Study Group of the Italian Neurological Society..

Mult Scler. 2016 Nov;22(13):1741-1749.

PMID:
26869527
19.

No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study).

Lanzillo R, Quarantelli M, Pozzilli C, Trojano M, Amato MP, Marrosu MG, Francia A, Florio C, Orefice G, Tedeschi G, Bellantonio P, Annunziata P, Grimaldi LM, Comerci M, Brunetti A, Bonavita V, Alfano B, Marini S, Brescia Morra V; ARIANNA study group..

Mult Scler. 2016 Aug;22(9):1163-73. doi: 10.1177/1352458515611222.

PMID:
26466947
20.

Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine.

Macdonell R, Nagels G, Laplaud DA, Pozzilli C, de Jong B, Martins da Silva A, Nicholas R, Lechner-Scott J, Gaebler JA, Agarwal S, Wang P, Yeh M, Hovenden M, Soelberg Sørensen P.

Mult Scler. 2016 Jun;22(7):944-54. doi: 10.1177/1352458515606809.

PMID:
26447066
Items per page

Supplemental Content

Loading ...
Support Center